Barnett AH - Search Results

1

Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes.

Farmer AJ, Perera R, Ward A, Heneghan C, Oke J, Barnett AH, Davidson MB, Guerci B, Coates V, Schwedes U, O'Malley S. Farmer AJ, et al. Among authors: barnett ah. BMJ. 2012 Feb 27;344:e486. doi: 10.1136/bmj.e486. BMJ. 2012. PMID: 22371867

2

Individual patient data meta-analysis of trials of self-monitoring of blood glucose in non-insulin treated type 2 diabetes: protocol for a systematic review.

Farmer AJ, Heneghan C, Barnett AH, Davidson MB, Guerci B, O'Kane M, Schwedes U, Perera R; Self-monitoring of blood glucose trialists collaboration. Farmer AJ, et al. Among authors: barnett ah. Prim Care Diabetes. 2009 May;3(2):117-21. doi: 10.1016/j.pcd.2009.03.002. Epub 2009 Apr 16. Prim Care Diabetes. 2009. PMID: 19375398

3

Insulin glargine in the treatment of type 1 and type 2 diabetes.

Barnett AH. Barnett AH. Vasc Health Risk Manag. 2006;2(1):59-67. doi: 10.2147/vhrm.2006.2.1.59. Vasc Health Risk Manag. 2006. PMID: 17319470 Free PMC article. Review.

4

Dosing of insulin glargine in the treatment of type 2 diabetes.

Barnett A. Barnett A. Clin Ther. 2007 Jun;29(6):987-99. doi: 10.1016/j.clinthera.2007.06.018. Clin Ther. 2007. PMID: 17692716 Review.

5

Cardiovascular risk factors and their management in 1282 adult people with type 1 diabetes.

Syed A, Hussain S, Nightingale P, De P, Charlton MH, Gangopadhyay K, Barnett AH, Narendran P. Syed A, et al. Among authors: barnett ah. Curr Med Res Opin. 2007 Dec;23(12):2921-7. doi: 10.1185/030079907X233313. Curr Med Res Opin. 2007. PMID: 17931464

6

Insulin for type 2 diabetes: choosing a second-line insulin regimen.

Barnett A, Begg A, Dyson P, Feher M, Hamilton S, Munro N. Barnett A, et al. Int J Clin Pract. 2008 Nov;62(11):1647-53. doi: 10.1111/j.1742-1241.2008.01909.x. Int J Clin Pract. 2008. PMID: 19143853 Free PMC article.

7

Drug evaluation: vildagliptin-metformin single-tablet combination.

Tahrani AA, Piya MK, Barnett AH. Tahrani AA, et al. Among authors: barnett ah. Adv Ther. 2009 Feb;26(2):138-54. doi: 10.1007/s12325-009-0010-0. Epub 2009 Mar 19. Adv Ther. 2009. PMID: 19288260 Review.

8

Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes mellitus.

Lloyd A, Nafees B, Barnett AH, Heller S, Ploug UJ, Lammert M, Bøgelund M. Lloyd A, et al. Among authors: barnett ah. Clin Ther. 2011 Sep;33(9):1258-67. doi: 10.1016/j.clinthera.2011.07.017. Epub 2011 Aug 20. Clin Ther. 2011. PMID: 21862132 Clinical Trial.

9

What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes.

Morgan CL, Poole CD, Evans M, Barnett AH, Jenkins-Jones S, Currie CJ. Morgan CL, et al. Among authors: barnett ah. J Clin Endocrinol Metab. 2012 Dec;97(12):4605-12. doi: 10.1210/jc.2012-3034. Epub 2012 Oct 17. J Clin Endocrinol Metab. 2012. PMID: 23076348

10

Future glucose-lowering drugs for type 2 diabetes.

Bailey CJ, Tahrani AA, Barnett AH. Bailey CJ, et al. Among authors: barnett ah. Lancet Diabetes Endocrinol. 2016 Apr;4(4):350-9. doi: 10.1016/S2213-8587(15)00462-3. Epub 2016 Jan 23. Lancet Diabetes Endocrinol. 2016. PMID: 26809680 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

440 results

Search Page

Filters